Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Chulbul M Ahmed & Howard M Johnson. (2013) The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis. JAK-STAT 2:4.
Read now
Read now
J. de Sá, G. Urbano & L. Reis. (2010) Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. Current Medical Research and Opinion 26:9, pages 2237-2242.
Read now
Read now
Slobodan M Jankovic. (2010) Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis. Journal of Inflammation Research 3, pages 25-31.
Read now
Read now
Keith C Hayes. (2007) Fampridine-SR for multiple sclerosis and spinal cord injury. Expert Review of Neurotherapeutics 7:5, pages 453-461.
Read now
Read now
Mathias Buttmann & Peter Rieckmann. (2007) Interferon-β1b in multiple sclerosis. Expert Review of Neurotherapeutics 7:3, pages 227-239.
Read now
Read now
Articles from other publishers (20)
Fatma BAYRAKDAR, Sibel A. ÖZKAN & Kamil Can AKÇALI. (2022) BETAFERON'UN COVID-19 İÇİN ANTİVİRAL AKTİVİTESİ. Ankara Universitesi Eczacilik Fakultesi Dergisi, pages 883-894.
Crossref
Crossref
Rajagopalan Vijayaraghavan. (2020) Autoinjector device for rapid administration of drugs and antidotes in emergency situations and in mass casualty management. Journal of International Medical Research 48:5, pages 030006052092601.
Crossref
Crossref
N. Yu. Lashch. (2020) Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist. Meditsinskiy sovet = Medical Council:2, pages 69-75.
Crossref
Crossref
Alyria Teixeira Dias, Sandra Bertelli Ribeiro de Castro, Caio César de Souza Alves, Marcilene Gomes Evangelista, Luan Cristian da Silva, Daniele Ribeiro de Lima Reis, Marco Antonio Machado, Maria Aparecida Juliano & Ana Paula Ferreira. (2018) Genistein modulates the expression of Toll-like receptors in experimental autoimmune encephalomyelitis. Inflammation Research 67:7, pages 597-608.
Crossref
Crossref
T. E. Shmidt. (2017) Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 117:11, pages 140.
Crossref
Crossref
Nicolas Boivin, Joanie Baillargeon, Prenitha Mercy Ignatius Arokia Doss, Andrée-Pascale Roy & Manu Rangachari. (2015) Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells. PLOS ONE 10:4, pages e0124802.
Crossref
Crossref
Chulbul M. AhmedHoward M. Johnson. (2014) Short Peptide Type I Interferon Mimetics: Therapeutics for Experimental Allergic Encephalomyelitis, Melanoma, and Viral Infections. Journal of Interferon & Cytokine Research 34:10, pages 802-809.
Crossref
Crossref
Martin Marziniak & Sven Meuth. (2014) Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. Advances in Therapy 31:9, pages 915-931.
Crossref
Crossref
Christiane Reick, Gisa Ellrichmann, Jan Thöne, Robert H. Scannevin, Carsten Saft, Ralf A. Linker & Ralf Gold. (2014) Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Experimental Neurology 257, pages 50-56.
Crossref
Crossref
Chulbul M. Ahmed, Ezra N. Noon-Song, Kaisa Kemppainen, Massimo P. Pascalli & Howard M. Johnson. (2013) Type I IFN receptor controls activated TYK2 in the nucleus: Implications for EAE therapy. Journal of Neuroimmunology 254:1-2, pages 101-109.
Crossref
Crossref
Reza Khorooshi & Trevor Owens. 2013. JAK-STAT Signalling. JAK-STAT Signalling
179
188
.
Fei Peng, Yinjue Wang, Lijing Sun, Yongdong Liu, Tao Hu, Guifeng Zhang, Guanghui Ma & Zhiguo Su. (2012) PEGylation of Proteins in Organic Solution: A Case Study for Interferon beta-1b. Bioconjugate Chemistry 23:9, pages 1812-1820.
Crossref
Crossref
Clare Fraser & Gordon T. Plant. 2011. Neuroinflammation. Neuroinflammation
253
276
.
CL Galligan, LM Pennell, TT Murooka, E Baig, B Majchrzak-Kita, R Rahbar & EN Fish. (2010) Interferon-β is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal 16:12, pages 1458-1473.
Crossref
Crossref
. (2010) Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma & Immunology 105:4, pages 259-273.e78.
Crossref
Crossref
Ana L. Romero-Weaver, Hsiang-Wen Wang, Håkan C. Steen, Anthony J. Scarzello, Veronica L. Hall, Faruk Sheikh, Raymond P. Donnelly & Ana M. Gamero. (2010) Resistance to IFN-α–Induced Apoptosis Is Linked to a Loss of STAT2. Molecular Cancer Research 8:1, pages 80-92.
Crossref
Crossref
Ute H. Webb. (2008) Early Interferon Beta Treatment in Multiple Sclerosis. Journal of Neuroscience Nursing 40:6, pages 356-361.
Crossref
Crossref
Oliver Neuhaus, Bernd C. Kieseier & Hans-Peter Hartung. (2007) Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Journal of the Neurological Sciences 259:1-2, pages 27-37.
Crossref
Crossref
Gavin Giovannoni, Olga Barbarash, Florence Casset-Semanaz, Amer Jaber, John King, Luanne Metz, Gabriel Pardo, James Simsarian, Per Soelberg Sørensen & Bettina Stubinski. (2007) Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics 29:6, pages 1128-1145.
Crossref
Crossref
Megan Burgess. (2005) The use of interferon beta-1b (Betaferon) in multiple sclerosis and the MS nurse's role. British Journal of Neuroscience Nursing 1:3, pages 132-138.
Crossref
Crossref